Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NP-G2-044 × Gynecologic × Clear all
NCT07109414 2026-03-09

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Novita Pharmaceuticals, Inc.

Phase 2/3 Active not recruiting
380 enrolled
Gynecologic

Ovarian Neoplasms

NCT03199586 2025-07-20

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals, Inc.

Phase 1 Completed
23 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡